. Author manuscript; available in PMC: 2009 Aug 1.

Published in final edited form as: Bioconjug Chem. 2008 Jul 12;19(8):1579–1587. doi: 10.1021/bc800110y

Table 2.

Biodistribution of ¹¹¹In-CHX-A” DTPA-Z₂₃₉₅-C, ¹¹¹In-DOTA-Z₂₃₉₅-C and ¹¹¹In-CHX-A” DTPA-Z₃₄₂ Affibody conjugates 4 h after iv injection in BALB/C nu/nu mice bearing SKOV-3 xenografts

	Uptake, % IA/g ^a
	¹¹¹In-CHX-A”	¹¹¹In-DOTA-	¹¹¹In-CHX-A”
	DTPA-Z₂₃₉₅-C	Z₂₃₉₅-C	DTPA-Z₃₄₂
blood	0.22 ± 0.05 ^d	0.25 ± 0.09	0.04 ± 0.01 ^c
lung	0.42 ± 0.03 ^c, ^d	0.31 ± 0.06	0.15 ± 0.05 ^c
liver	1.4 ± 0.3 ^d	1.6 ± 0.6	0.63 ± 0.08 ^c
spleen	0.5 ± 0.1 ^d	0.5 ± 0.2	0.16 ± 0.02 ^c
kidney	227 ± 18 ^c, ^d	169 ± 36	184 ± 17
tumor	17 ± 5 ^d	8 ± 2	8 ± 2
muscle	0.12 ± 0.03 ^c, ^d	0.07 ± 0.02	0.03 ± 0.01 ^c
bone	0.21 ± 0.05 ^d	0.2 ± 0.2	0.09 ± 0.03
GI tract b	6 ± 2 ^c	0.9 ± 0.2	4.6 ± 0.3 ^c
carcass b	8 ± 2 ^c, ^d	2.9 ± 0.3	1.9 ± 0.4 ^c

data presented as average ± SD (n = 4) of per cent of injected activity per gram (% IA/g);

for intestine (together with content) and carcass, data presented as per cent of injected activity per whole sample (% IA);

significant difference (p < 0.05) with ¹¹¹In-DOTA-Z₂₃₉₅-C at the same time point;

significant difference (p < 0.05) with ¹¹¹In-CHX-A” DTPA-Z₃₄₂ at the same time point;